Published in Gastroenterology on August 23, 2009
Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic | NCT03580577
Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience. Aliment Pharmacol Ther (2017) 1.14
Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94
Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci (2013) 0.93
The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J (2011) 0.91
Global assays of hemostasis. Curr Opin Hematol (2014) 0.86
Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World J Gastroenterol (2014) 0.86
Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci (2011) 0.85
Venous thromboembolism in cirrhosis: a review of the literature. Can J Gastroenterol (2012) 0.85
Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterol (2011) 0.84
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis. World J Hepatol (2015) 0.83
High early cardiovascular mortality after liver transplantation. Liver Transpl (2014) 0.82
Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesis. Med Sci Monit (2012) 0.81
Association between Liver Disease and Intracranial Hemorrhage. J Stroke Cerebrovasc Dis (2015) 0.81
Early prophylactic anticoagulation for portal vein system thrombosis after splenectomy: A systematic review and meta-analysis. Biomed Rep (2016) 0.80
Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost (2012) 0.80
Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran. Hepat Mon (2015) 0.79
Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surg (2013) 0.79
Impact of early reoperation following living-donor liver transplantation on graft survival. PLoS One (2014) 0.78
Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol (2014) 0.78
Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol (2016) 0.78
Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol (2013) 0.77
Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes? ScientificWorldJournal (2014) 0.77
Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. Biomed Res Int (2013) 0.77
Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol (2015) 0.77
Association of conventional haemostasis and coagulation tests with the risk of acute upper gastrointestinal bleeding in liver cirrhosis: a retrospective study. Gastroenterol Rep (Oxf) (2015) 0.76
The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage. Saudi J Gastroenterol (2015) 0.75
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One (2014) 0.75
Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. PLoS One (2016) 0.75
Anticoagulation and antiplatelets as prophylaxis for hepatic artery thrombosis after liver transplantation. World J Hepatol (2015) 0.75
Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention. Transplant Direct (2016) 0.75
Imbalance of pro- vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis. PLoS One (2015) 0.75
Resveratrol Reduces the Incidence of Portal Vein System Thrombosis after Splenectomy in a Rat Fibrosis Model. Oxid Med Cell Longev (2016) 0.75
Risk of Bleeding in End-Stage Liver Disease Patients Undergoing Cardiac Catheterization. Tex Heart Inst J (2015) 0.75
Thromboelastographic Evaluation of Coagulation in Patients With Liver Disease. Ann Lab Med (2017) 0.75
Severe gastric variceal haemorrhage due to splenic artery thrombosis and consecutive arterial bypass. BMC Surg (2011) 0.75
Changing Concepts of Cirrhotic Coagulopathy. Am J Gastroenterol (2016) 0.75
Complications and 30-day Outcomes Associated With Venous Thromboembolism in the Pediatric Orthopaedic Surgical Population. J Am Acad Orthop Surg (2016) 0.75
Anticoagulation in cirrhosis: a new paradigm? Clin Mol Hepatol (2017) 0.75
Changing common sense: Anti-platelet/coagulation therapy against cirrhosis. World J Hepatol (2015) 0.75
Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep (2017) 0.75
The role of thromboelastometry in the assessment and treatment of coagulopathy in liver transplant patients. Einstein (Sao Paulo) (2017) 0.75
Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort. Eur Radiol (2016) 0.75
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut (2009) 6.50
The coagulopathy of chronic liver disease. N Engl J Med (2011) 5.63
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med (2008) 3.96
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology (2010) 2.87
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (2010) 2.82
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol (2011) 2.78
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med (2013) 2.64
Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int (2012) 2.60
Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology (2005) 2.41
Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica (2003) 2.38
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology (2011) 2.36
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology (2009) 2.33
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol (2004) 2.30
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology (2008) 2.25
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol (2013) 2.23
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol (2013) 2.19
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int (2014) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology (2010) 2.06
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology (2007) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology (2004) 2.01
Living near major traffic roads and risk of deep vein thrombosis. Circulation (2009) 1.98
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol (2006) 1.90
Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology (2013) 1.89
Complications, limitations, and failures of capsule endoscopy: a review of 733 cases. Gastrointest Endosc (2005) 1.86
The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology (2007) 1.86
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood (2002) 1.85
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med (2003) 1.75
Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation (2004) 1.73
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood (2011) 1.67
Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol (2007) 1.67
Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med (2008) 1.65
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol (2005) 1.63
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol (2002) 1.62
Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost (2002) 1.62
Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol (2005) 1.61
New antiplatelet agents: why they are needed. Eur J Intern Med (2009) 1.58
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood (2012) 1.58
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (2003) 1.57
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 1.57
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int (2013) 1.57
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica (2003) 1.56
How I treat rare venous thromboses. Blood (2008) 1.56
Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med (2009) 1.53
Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol (2007) 1.53
A new era for anticoagulants. Eur J Intern Med (2009) 1.53
Air pollution, smoking, and plasma homocysteine. Environ Health Perspect (2006) 1.53
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50
Literature review and recommendations for clinical application of Colon Capsule Endoscopy. Dig Liver Dis (2010) 1.50
Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant (2012) 1.49
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology (2012) 1.49
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol (2010) 1.47
Small bowel capsule endoscopy in 2007: indications, risks and limitations. World J Gastroenterol (2007) 1.44
Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. Intern Emerg Med (2013) 1.44
Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol (2002) 1.43
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica (2008) 1.41
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica (2008) 1.41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opin Emerg Drugs (2012) 1.40
Internal and geriatric medicine: an alliance for the challenges of the elderly. Eur J Intern Med (2012) 1.40
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40
Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Intern Emerg Med (2006) 1.39
The hemostatic balance revisited through the lessons of mankind evolution. Intern Emerg Med (2008) 1.39
Global coagulation in myeloproliferative neoplasms. Ann Hematol (2013) 1.38
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38